Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) Profit After Tax (2016 - 2025)

Collegium Pharmaceutical (COLL) has 10 years of Profit After Tax data on record, last reported at $45.0 million in Q4 2025.

  • For Q4 2025, Profit After Tax rose 259.21% year-over-year to $45.0 million; the TTM value through Dec 2025 reached $90.9 million, up 31.43%, while the annual FY2025 figure was $108.6 million, 15.75% up from the prior year.
  • Profit After Tax reached $45.0 million in Q4 2025 per COLL's latest filing, up from $31.5 million in the prior quarter.
  • Across five years, Profit After Tax topped out at $72.8 million in Q2 2021 and bottomed at -$25.0 million in Q4 2021.
  • Average Profit After Tax over 5 years is $12.7 million, with a median of $12.3 million recorded in 2024.
  • Peak YoY movement for Profit After Tax: plummeted 459.79% in 2021, then skyrocketed 4415.1% in 2023.
  • A 5-year view of Profit After Tax shows it stood at -$25.0 million in 2021, then skyrocketed by 71.24% to -$7.2 million in 2022, then soared by 543.67% to $31.9 million in 2023, then tumbled by 60.75% to $12.5 million in 2024, then skyrocketed by 259.21% to $45.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Profit After Tax were $45.0 million in Q4 2025, $31.5 million in Q3 2025, and $12.0 million in Q2 2025.